Vident Advisory LLC Boosts Holdings in Sana Biotechnology, Inc. $SANA

Vident Advisory LLC increased its holdings in Sana Biotechnology, Inc. (NASDAQ:SANA) by 37.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 59,617 shares of the company’s stock after buying an additional 16,326 shares during the quarter. Vident Advisory LLC’s holdings in Sana Biotechnology were worth $100,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Sana Biotechnology by 2.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 280,731 shares of the company’s stock worth $457,000 after buying an additional 6,613 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Sana Biotechnology by 2.1% in the first quarter. Bank of New York Mellon Corp now owns 344,058 shares of the company’s stock worth $578,000 after buying an additional 7,230 shares during the last quarter. Hsbc Holdings PLC boosted its holdings in shares of Sana Biotechnology by 26.5% in the first quarter. Hsbc Holdings PLC now owns 41,377 shares of the company’s stock worth $65,000 after buying an additional 8,673 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Sana Biotechnology by 5.4% in the first quarter. Rhumbline Advisers now owns 182,134 shares of the company’s stock worth $306,000 after buying an additional 9,359 shares during the last quarter. Finally, ProShare Advisors LLC boosted its holdings in shares of Sana Biotechnology by 25.4% in the fourth quarter. ProShare Advisors LLC now owns 47,808 shares of the company’s stock worth $78,000 after buying an additional 9,679 shares during the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on SANA shares. JMP Securities reissued a “market outperform” rating and issued a $5.00 price objective on shares of Sana Biotechnology in a report on Tuesday, June 24th. Morgan Stanley began coverage on shares of Sana Biotechnology in a report on Thursday, July 3rd. They set an “overweight” rating and a $12.00 price target on the stock. Six analysts have rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $8.00.

Sana Biotechnology Price Performance

Sana Biotechnology stock opened at $2.91 on Thursday. The stock has a market cap of $692.03 million, a P/E ratio of -2.75 and a beta of 1.88. Sana Biotechnology, Inc. has a 1 year low of $1.26 and a 1 year high of $7.30. The firm’s 50 day moving average price is $3.72 and its 200-day moving average price is $2.70.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.04. As a group, equities analysts expect that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.